NASDAQ · Biotechnology

Altamira Therapeutics Ltd. (CYTO) Stock

$0.30 +100.00% NASDAQ: CYTO Healthcare

Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved.

Valuation

MetricValue
Price$0.30
Market Cap$1.13M
P/E Ratio-0.02
P/B Ratio0.02
P/S Ratio0.00
EPS (TTM)$-14.80
52-Week High$0.42
52-Week Low$0.30
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-111.64%
ROA-84.03%
ROCE-79.01%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.05
Current Ratio1.32

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$0$0—
Operating Profit$-5.0M$-5.0M$-18.0M$-6.0M—
Net Profit$-8.0M$-17.0M$-27.0M$-7.0M—
EPS$-545.41$-515.11$-582.58$-14.80—
Op Margin-3027.9%-8361.4%-5894.3%——

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$21.0M$19.0M$6.0M$8.0M$9.0M
Total Liabilities$4.0M$6.0M$15.0M$1.0M$2.0M
Cash$11.0M$1.0M$0$1.0M$1.0M
Borrowings$1.0M$1.0M$6.0M$0$0

Latest News

CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights PR Newswire · Jul 20, 2026 CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why Zacks · Jul 8, 2026 OTC Markets Life Sciences Investor Forum: Dr. Phillip Chan, CEO, and Pete Mariani, CFO, of CytoSorbents with Zacks SCR’s Tom Kerr, CFA Zacks Small Cap Research · Jul 8, 2026 Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing GlobeNewswire · Jun 26, 2026 Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th GlobeNewswire · Jun 23, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-5.0M$-14.0M$-9.0M$-12.0M$-6.0M
Investing Cash Flow$-5.0M$-7.0M$-4.0M$1.0M$0
Financing Cash Flow$15.0M$7.0M$4.0M$10.0M$7.0M
Net Cash Flow$10.0M$-10.0M$-1.0M$1.0M$0
Free Cash Flow$-7.0M$-17.0M$-11.0M$-12.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.09
FCF Yield-548.42%
Quick Ratio1.32
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved. Its marketed offerings include Bentrio, a non-pharmaceutical nasal spray designed for individual protection against prevalent airborne viruses and allergens. The company is also heavily invested in developing RNA therapeutics specifically for extrahepatic targets. This includes their preclinical OligoPhore and SemaPhore platforms, engineered for the effective delivery of oligonucleotides and mRNA. In its clinical-stage portfolio, AM-125 is undergoing Phase II trials for the intranasal treatment of vertigo. Additionally, Keyzilen and Sonsuvi are both in Phase III clinical development; Keyzilen is focused on acute inner ear tinnitus, and Sonsuvi addresses acute inner ear hearing loss. Established in 2003 and headquartered in Hamilton, Bermuda, Altamira Therapeutics conducts operations across Switzerland, the United States, Europe, and Australia. The company officially adopted the name Altamira Therapeutics Ltd. in July 2021, prior to which it was known as Auris Medical Holding Ltd.

Altamira Therapeutics Ltd. is headquartered in BM.

Altamira Therapeutics Ltd. (CYTO) stock trades at $0.30 with a market capitalization of $1.13M. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of 0.02, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.30 and $0.42, and currently trades 28.6% below its 52-week high.

On profitability, Altamira Therapeutics Ltd. generates a return on equity (ROE) of -111.64%, return on capital employed of -79.01%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: altamiratherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides